These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1080 related items for PubMed ID: 25236687

  • 1. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
    Villarreal-Garza C, Alvarez-Gómez RM, Pérez-Plasencia C, Herrera LA, Herzog J, Castillo D, Mohar A, Castro C, Gallardo LN, Gallardo D, Santibáñez M, Blazer KR, Weitzel JN.
    Cancer; 2015 Feb 01; 121(3):372-8. PubMed ID: 25236687
    [Abstract] [Full Text] [Related]

  • 2. Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network.
    Weitzel JN, Clague J, Martir-Negron A, Ogaz R, Herzog J, Ricker C, Jungbluth C, Cina C, Duncan P, Unzeitig G, Saldivar JS, Beattie M, Feldman N, Sand S, Port D, Barragan DI, John EM, Neuhausen SL, Larson GP.
    J Clin Oncol; 2013 Jan 10; 31(2):210-6. PubMed ID: 23233716
    [Abstract] [Full Text] [Related]

  • 3. The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer.
    Villarreal-Garza C, Weitzel JN, Llacuachaqui M, Sifuentes E, Magallanes-Hoyos MC, Gallardo L, Alvarez-Gómez RM, Herzog J, Castillo D, Royer R, Akbari M, Lara-Medina F, Herrera LA, Mohar A, Narod SA.
    Breast Cancer Res Treat; 2015 Apr 10; 150(2):389-94. PubMed ID: 25716084
    [Abstract] [Full Text] [Related]

  • 4. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
    Riahi A, Chabouni-Bouhamed H, Kharrat M.
    Cancer Genet; 2017 Jan 10; 210():22-27. PubMed ID: 28212807
    [Abstract] [Full Text] [Related]

  • 5. Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations.
    Alemar B, Herzog J, Brinckmann Oliveira Netto C, Artigalás O, Schwartz IVD, Matzenbacher Bittar C, Ashton-Prolla P, Weitzel JN.
    Cancer Genet; 2016 Sep 10; 209(9):417-422. PubMed ID: 27425403
    [Abstract] [Full Text] [Related]

  • 6. Full-exon pyrosequencing screening of BRCA germline mutations in Mexican women with inherited breast and ovarian cancer.
    Vaca-Paniagua F, Alvarez-Gomez RM, Fragoso-Ontiveros V, Vidal-Millan S, Herrera LA, Cantú D, Bargallo-Rocha E, Mohar A, López-Camarillo C, Pérez-Plasencia C.
    PLoS One; 2012 Sep 10; 7(5):e37432. PubMed ID: 22655046
    [Abstract] [Full Text] [Related]

  • 7. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Alhuqail AJ, Alzahrani A, Almubarak H, Al-Qadheeb S, Alghofaili L, Almoghrabi N, Alhussaini H, Park BH, Colak D, Karakas B.
    Breast Cancer Res Treat; 2018 Apr 10; 168(3):695-702. PubMed ID: 29297111
    [Abstract] [Full Text] [Related]

  • 8. [Comparison of hereditary breast and ovarian cancer syndrome and sporadic ovarian cancer in ovarian cancer BRCA mutations].
    Duan RR, Sun LX, Zhao HW.
    Zhonghua Fu Chan Ke Za Zhi; 2021 Nov 25; 56(11):788-795. PubMed ID: 34823292
    [Abstract] [Full Text] [Related]

  • 9. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    Demir S, Tozkir H, Gurkan H, Atli EI, Yalcintepe S, Atli E, Sezer YA, Eker D, Tuncbilek N, Tastekin E, Ozen Y, Cicin I.
    J BUON; 2020 Nov 25; 25(3):1337-1347. PubMed ID: 32862574
    [Abstract] [Full Text] [Related]

  • 10. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F, Salhi N, Bakour R, Adane S, Boualga K, Maillet P.
    Dis Markers; 2012 Nov 25; 32(6):343-53. PubMed ID: 22684231
    [Abstract] [Full Text] [Related]

  • 11. Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru.
    Abugattas J, Llacuachaqui M, Allende YS, Velásquez AA, Velarde R, Cotrina J, Garcés M, León M, Calderón G, de la Cruz M, Mora P, Royer R, Herzog J, Weitzel JN, Narod SA.
    Clin Genet; 2015 Oct 25; 88(4):371-5. PubMed ID: 25256238
    [Abstract] [Full Text] [Related]

  • 12. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P, Janoutova J, Hermanova B.
    Mol Biol Rep; 2020 Apr 25; 47(4):2763-2769. PubMed ID: 32180084
    [Abstract] [Full Text] [Related]

  • 13. The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer.
    Kwong A, Chen J, Shin VY, Ho JC, Law FB, Au CH, Chan TL, Ma ES, Ford JM.
    Cancer Genet; 2015 Sep 25; 208(9):448-54. PubMed ID: 26271414
    [Abstract] [Full Text] [Related]

  • 14. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
    Maistro S, Teixeira N, Encinas G, Katayama ML, Niewiadonski VD, Cabral LG, Ribeiro RM, Gaburo Junior N, de Gouvêa AC, Carraro DM, Sabino EC, Diz MD, Chammas R, de Bock GH, Folgueira MA.
    BMC Cancer; 2016 Dec 03; 16(1):934. PubMed ID: 27914478
    [Abstract] [Full Text] [Related]

  • 15. Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis.
    Kwong A, Ng EK, Wong CL, Law FB, Au T, Wong HN, Kurian AW, West DW, Ford JM, Ma ES.
    PLoS One; 2012 Dec 03; 7(9):e43994. PubMed ID: 22970155
    [Abstract] [Full Text] [Related]

  • 16. Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients.
    Sokolenko AP, Sokolova TN, Ni VI, Preobrazhenskaya EV, Iyevleva AG, Aleksakhina SN, Romanko AA, Bessonov AA, Gorodnova TV, Anisimova EI, Savonevich EL, Bizin IV, Stepanov IA, Krivorotko PV, Berlev IV, Belyaev AM, Togo AV, Imyanitov EN.
    Breast Cancer Res Treat; 2020 Nov 03; 184(1):229-235. PubMed ID: 32776218
    [Abstract] [Full Text] [Related]

  • 17. Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling.
    Melki R, Melloul M, Aissaoui S, El Harroudi T, Boukhatem N.
    BMC Cancer; 2023 Apr 13; 23(1):339. PubMed ID: 37055759
    [Abstract] [Full Text] [Related]

  • 18. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL.
    Breast Cancer Res; 2011 Feb 28; 13(1):R20. PubMed ID: 21356067
    [Abstract] [Full Text] [Related]

  • 19. BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer.
    El Saghir NS, Zgheib NK, Assi HA, Khoury KE, Bidet Y, Jaber SM, Charara RN, Farhat RA, Kreidieh FY, Decousus S, Romero P, Nemer GM, Salem Z, Shamseddine A, Tfayli A, Abbas J, Jamali F, Seoud M, Armstrong DK, Bignon YJ, Uhrhammer N.
    Oncologist; 2015 Apr 28; 20(4):357-64. PubMed ID: 25777348
    [Abstract] [Full Text] [Related]

  • 20. Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families.
    Rudnicka H, Debniak T, Cybulski C, Huzarski T, Gronwald J, Lubinski J, Gorski B.
    Mol Biol Rep; 2013 Dec 28; 40(12):6619-23. PubMed ID: 24065545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.